Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.01.23	Biotech Stocks Facing FDA Decision In February 2023 (RTTNews)
27.01.23	Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent (RTTNews)
24.01.23	Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition (PR Newswire)
19.01.23	Erste Schätzungen: Regeneron Pharmaceuticals präsentiert Quartalsergebnisse (finanzen.net)
05.01.23	Sensei Biotherapeutics Enters Clinical Supply Agreement With Regeneron For Libtayo (RTTNews)
23.12.22	Regeneron Granted Marketing Authorization For Libtayo In Japan For Recurrent Cervical Cancer (RTTNews)
23.12.22	Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer (PR Newswire)
22.12.22	Regeneron : Positive Dupixent Phase 3 Results In Eosinophilic Esophagitis Published (RTTNews)
21.12.22	Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine (PR Newswire)
19.12.22	Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
16.12.22	Regeneron: CHMP Recommends Dupixent For EU Approval To Treat Eosinophilic Esophagitis (RTTNews)
16.12.22	Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis (PR Newswire)
15.12.22	Regeneron, Sanofi: Dupixent Approved In EU For Prurigo Nodularis (RTTNews)
15.12.22	Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis (PR Newswire)
12.12.22	Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial (PR Newswire)
12.12.22	Regeneron Pharma Announces Positive Data From Mid-stage Study Of Linvoseltamab (RTTNews)
12.12.22	Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma (PR Newswire)
12.12.22	Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year (PR Newswire)
11.12.22	Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH (PR Newswire)
01.12.22	Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types (PR Newswire)
30.11.22	Regeneron Pharma: Evkeeza SBLA Granted FDA Priority Review (RTTNews)
30.11.22	Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review (PR Newswire)
25.11.22	Form 4 872589 (RSS)
22.11.22	Regeneron :EC Oks Libtayo As First Immunotherapy In Second Line Recurrent/Metastatic Cervical Cancer (RTTNews)
22.11.22	Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology (PR Newswire)
17.11.22	Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer (PR Newswire)
11.11.22	Bayer-Aktie tiefer: Patentschutz-Verlängerung für Bayer-Medikament Eylea geplant (AWP) Bayer kann sich Hoffnung auf eine kurze Verlängerung des Patentschutzes für seinen Kassenschlager Eylea gegen bestimmte Augenerkrankungen machen.» mehr
11.11.22	Regeneron, Sanofi: CHMP Recommends Approval Of Dupixent In The EU (RTTNews)
11.11.22	Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis (PR Newswire)
10.11.22	Form 4 872589 (RSS)
08.11.22	Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) (PR Newswire)
05.11.22	Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration (PR Newswire)
03.11.22	Regeneron Announces Investor Conference Presentations (PR Newswire)
03.11.22	Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders (PR Newswire)
03.11.22	Regeneron Pharmaceuticals Q3 Profit Decreases, but beats estimates (RTTNews)
03.11.22	Regeneron Reports Third Quarter 2022 Financial and Operating Results (PR Newswire)
03.11.22	Form 8-K 872589 (RSS)
03.11.22	Form 10-Q 872589 (RSS)
02.11.22	Ausblick: Regeneron Pharmaceuticals zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
02.11.22	Form 4 872589 (RSS)
28.10.22	Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award (PR Newswire)
21.10.22	Regeneron: FDA Grants Pediatric Exclusivity For EYLEA (RTTNews)
21.10.22	Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection (PR Newswire)
19.10.22	Erste Schätzungen: Regeneron Pharmaceuticals gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
14.10.22	Regeneron Pharma: CHMP Adopts Positive Opinion For Libtayo - Quick Facts (RTTNews)
14.10.22	Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer (PR Newswire)
12.10.22	Regeneron: EYLEA SBLA Gets FDA Priority Review - Quick Facts (RTTNews)
12.10.22	EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review (PR Newswire)
11.10.22	Regeneron Reports Positive Results From Dupixent Phase 3 Trial In 1 To 11 Yrs With EoE (RTTNews)
11.10.22	Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

31.10.24

NASDAQ-Handel NASDAQ 100 schlussendlich in Rot

31.10.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone

31.10.24

NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell

31.10.24

Zurückhaltung in New York: So performt der NASDAQ 100 aktuell

31.10.24

Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus